Update on Smallpox Preparedness
Author Information
Author(s): James W. LeDuc, Peter B. Jahrling
Primary Institution: Centers for Disease Control and Prevention
Hypothesis
The study aims to assess the current state of smallpox vaccine production and variola virus research in light of potential bioterrorism threats.
Conclusion
The research and vaccine production efforts will enhance preparedness against the potential use of smallpox as a biological weapon.
Supporting Evidence
- Only 15.4 million doses of smallpox vaccine exist in the United States.
- Forty million doses of a new smallpox vaccine will be produced initially.
- Research teams are coordinating to maximize information before the destruction of variola virus stocks.
- 274 antiviral drug compounds were screened for activity against variola and other orthopox viruses.
- Animal models are being developed to replicate human smallpox for testing antiviral drugs.
Takeaway
Scientists are working on making more smallpox vaccine and studying the virus to be ready in case it is used as a weapon.
Methodology
The study involved the production of a new smallpox vaccine and research on variola virus isolates under biosafety level 4 conditions.
Limitations
The study is limited by the historical context of smallpox eradication and the challenges of working with a virus that has not been studied extensively in recent decades.
Want to read the original?
Access the complete publication on the publisher's website